(40 Patient Screening Kits) Hemoccult ICT is the latest and most advanced fecal occult blood test (FOBT) in the Hemoccult product line. An immunochemical FOBT (iFOBT) with high specificity and sensitivity, Hemoccult ICT is clinically proven to detect bleeding associated with more cancers and polyps than traditional guaiac-based FOBTs. Because of its superior specificity for lower GI bleeding, Hemoccult ICT is an ideal screening tool for colorectal cancer (CRC), and this specificity also reduces the number of false positive test results. Safe and non invasive, Hemoccult ICT is very patient friendly, as there are no diet or drug restrictions for patients to follow while they are using it, which helps increase patient compliance. (FDA 510K#: K808012) Each patient screening kit includes 1 dispensing envelope, 3 collection cards, 3 applicator sticks, and 1 pouch. Hemoccult and Hemoccult II are registered trademarks of Beckman Coulter, Inc. SENSA is a registered trademark of SmithKline Diagnostics, Inc.
- For identifying gastrointestinal bleeding
- Not drug restriction or special dietary concerns
- Now available in convenient 2 or 3 day patient collection kits
- All slides stable for 14 days
- FDA Cleared and CLIA waived
- G0328QW - Fecal blood scrn immunoassay National Average Reimbursement 2019: $18.05
- National Average Reimbursement 2019: $18.05
- 82274QW - Assay test for blood fecal National Average Reimbursement 2019: $17.67
- National Average Reimbursement 2019: $17.67
